Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients

Golconda, Muralikrishna; Valente, John F.; Bejarano, P.A.; Gilinsky, Norman H.; First, M. Roy

doi:10.1016/s0041-1345(98)01531-0

Cited by 20 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is no clear correlation between MPA AUC or MPA trough levels and efficacy, these low levels may have contributed to the moderate incidence of acute GVHD in this trial. There were no definitive MMF-associated toxicities appreciated in this trial, although the one case of cecal ulceration and perforation is a reported toxicity of MMF described in the solid organ transplantation literature 51 . Of note, the combination of sirolimus and MMF did not appear to delay ANC recovery in this trial.…”

Section: Discussionmentioning

confidence: 72%

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Johnston

Florek

Armstrong

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

We investigated sirolimus and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in patients with advanced hematologic malignancies receiving myeloablative hematopoietic cell transplantation (HCT) from HLA-identical sibling donors. Based on pre-study stopping rules, the trial was closed to accrual after enrollment of 11 adult patients. Seven of the 11 patients received busulfan-containing preparative regimens. Sirolimus was discontinued in 3 patients due to toxicity-related events of severe sinusoidal obstructive syndrome, portal vein thrombosis, altered mental status and in 1 patient due to risk of poor wound healing. Six of the 11 patients developed grade II-IV acute GVHD (AGVHD) a median of 15.5 days post-HCT. Two of 3 patients with grade IV AGVHD had sirolimus discontinued by 9 days post-HCT. All patients responded to AGVHD therapy without GVHD-related deaths. There were 2 nonrelapse- and 2 relapse-related deaths. At a median follow-up of 38 months (2–47 months), 7 of 11 patients were alive without disease. MMF and sirolimus GVHD prophylaxis did not reduce the risk of acute GVHD, however, there were no GVHD-related deaths. The severe toxicities in the patients receiving the busulfan-containing preparative regimens limited the continued use of sirolimus and MMF for the prevention of AGVHD.

show abstract

Section: Discussionmentioning

confidence: 72%

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Johnston

Florek

Armstrong

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Indeed, to date only 1 such case has been well documented. 7 We now present the first reported gliosarcoma arising from an irradiated anaplastic ependymoma and only the second example of a gliosarcoma arising from an ependymal neoplasm in general.…”

Section: Gliosarcoma Arising From An Anaplastic Ependymoma: a Case Rementioning

confidence: 85%

Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis

Brunt

Bisceglie

2004

Human Pathology

View full text Add to dashboard Cite

“…The appearance of colonic ulcers 20 and perforations 21 during MMF treatment suggests that it influences tissue maintenance or repair 22 , and there is experimental evidence that it impairs anastomotic healing 6 . In the present study, measurement of bursting pressure, colonic crypt depth and proliferating cells has further demonstrated a negative effect of MMF on mucosal healing and anastomotic stability.…”

Section: Discussionmentioning

confidence: 99%

Insulin-like growth factor I improves aspects of mycophenolate mofetil-impaired anastomotic healing in an experimental model

Inglin

Baumann

Wagner

et al. 2008

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients

Cited by 20 publications

References 7 publications

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis

Insulin-like growth factor I improves aspects of mycophenolate mofetil-impaired anastomotic healing in an experimental model

Contact Info

Product

Resources

About